NASDAQ$APGE
Apogee Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Apogee Therapeutics reported full year 2024 financial results and provided pipeline progress.
Apogee Therapeutics reported full year 2024 financial results, highlighting the accelerated execution of the Phase 2 APEX clinical trial for APG777 and the positive interim Phase 1 results for APG990. The company's cash, cash equivalents, and marketable securities totaled $731.1 million, providing a runway into Q1 2028.
- Phase 2 APEX clinical trial for APG777 is progressing faster than expected.
- APG279 Phase 1b head-to-head study vs. DUPIXENT is supported by positive APG990 interim Phase 1 results.
- APG990 demonstrated potential for three- and six-month dosing in combination with APG777.
- Cash, cash equivalents and marketable securities totaled $731.1 million, providing runway into Q1 2028.
Headline financials
Revenue & EPS history
Apogee · Revenue · Quarterly
$0
Forward guidance
Apogee Therapeutics is looking forward to an exciting and productive 2025 with several meaningful catalysts expected.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2024
+5.6%
Avg return
Earnings day
+9.2%
Avg return
5 days after
+10.9%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+59.8%
Q4 2023
Best reaction
-12.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +4.4% | +20.3% | |
| Q3 2025 | +3.8% | +19.7% | +39.0% | |
| Q2 2025 | -2.2% | +5.4% | +5.9% | |
| Q1 2025 | -0.0% | -1.1% | +9.4% | |
| Q4 2024 | -0.2% | +14.9% | +20.3% | |
| Q3 2024 | -12.7% | -21.8% | -26.7% | |
| Q2 2024 | +9.7% | +11.7% | +25.0% | |
| Q1 2023 | +1.5% | -5.5% | -16.7% | |
| Q1 2024 | +1.5% | -5.5% | -16.7% | |
| Q4 2023 | +59.8% | +61.8% | +41.4% | |
| Q3 2023 | +12.8% | +20.6% | +45.9% | |
| Q3 2022 | +12.8% | +20.6% | +45.9% | |
| Q4 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2023 | -1.1% | +4.0% | -9.6% | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro